Ginkgo Bioworks Statistics Share Statistics Ginkgo Bioworks has 58.53M
shares outstanding. The number of shares has increased by 5.32%
in one year.
Shares Outstanding 58.53M Shares Change (YoY) 5.32% Shares Change (QoQ) 6.36% Owned by Institutions (%) 56.8% Shares Floating 49.9M Failed to Deliver (FTD) Shares 2,184 FTD / Avg. Volume 0.15%
Short Selling Information The latest short interest is 10.34M, so 17.67% of the outstanding
shares have been sold short.
Short Interest 10.34M Short % of Shares Out 17.67% Short % of Float 22.91% Short Ratio (days to cover) 7.42
Valuation Ratios The PE ratio is -0.93 and the forward
PE ratio is -2.51.
Ginkgo Bioworks's PEG ratio is
0.02.
PE Ratio -0.93 Forward PE -2.51 PS Ratio 2.24 Forward PS 3.3 PB Ratio 0.71 P/FCF Ratio -1.33 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Ginkgo Bioworks.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.62,
with a Debt / Equity ratio of 0.65.
Current Ratio 5.62 Quick Ratio 5.62 Debt / Equity 0.65 Debt / EBITDA -0.97 Debt / FCF -1.22 Interest Coverage -5954.86
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $272.23K Profits Per Employee $-655.91K Employee Count 834 Asset Turnover 0.16 Inventory Turnover n/a
Taxes Income Tax -479K Effective Tax Rate 0.09%
Stock Price Statistics The stock price has increased by 13.36% in the
last 52 weeks. The beta is 1.51, so Ginkgo Bioworks's
price volatility has been higher than the market average.
Beta 1.51 52-Week Price Change 13.36% 50-Day Moving Average 10.56 200-Day Moving Average 9.34 Relative Strength Index (RSI) 50.65 Average Volume (20 Days) 1,464,519
Income Statement In the last 12 months, Ginkgo Bioworks had revenue of 227.04M
and earned -547.03M
in profits. Earnings per share was -10.54.
Revenue 227.04M Gross Profit 188.49M Operating Income -559.76M Net Income -547.03M EBITDA -484.39M EBIT -547.41M Earnings Per Share (EPS) -10.54
Full Income Statement Balance Sheet The company has 561.57M in cash and 467.73M in
debt, giving a net cash position of 93.84M.
Cash & Cash Equivalents 561.57M Total Debt 467.73M Net Cash 93.84M Retained Earnings -5.84B Total Assets 1.29B Working Capital 448.87M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -319.58M
and capital expenditures -62.54M, giving a free cash flow of -382.13M.
Operating Cash Flow -319.58M Capital Expenditures -62.54M Free Cash Flow -382.13M FCF Per Share -7.36
Full Cash Flow Statement Margins Gross margin is 83.02%, with operating and profit margins of -246.54% and -240.94%.
Gross Margin 83.02% Operating Margin -246.54% Pretax Margin -241.15% Profit Margin -240.94% EBITDA Margin -213.35% EBIT Margin -246.54% FCF Margin -168.31%
Dividends & Yields DNA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for DNA is $8.5,
which is -28.5% lower than the current price. The consensus rating is "Hold".
Price Target $8.5 Price Target Difference -28.5% Analyst Consensus Hold Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 20, 2024. It was a
backward
split with a ratio of 1:40.
Last Split Date Aug 20, 2024 Split Type backward Split Ratio 1:40
Scores Altman Z-Score -6.23 Piotroski F-Score 3
